alexa Mortality Reduction with Administration of Abciximab during Primary PCI is Confined to STEMI Patients with Complex Lesions | OMICS International | Abstract
ISSN: 2329-6607

Cardiovascular Pharmacology: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Mortality Reduction with Administration of Abciximab during Primary PCI is Confined to STEMI Patients with Complex Lesions

Allan Zeeberg Iversen1*, Soren Galatius1, Sune Pedersen1, Ulrik Abildgaard1 and Jan Skov Jensen1,2

1Department of Cardiology, Gentofte University Hospital, Denmark

2Clinical Institute of Surgery and Internal Medicine, Faculty of Health Science, University of Copenhagen, Denmark

*Corresponding Author:
Allan Zeeberg Iversen
Department of Cardiology
Gentofte University Hospital
Niels Andersens Vej, Denmark
Tel: +4524892476
Fax: +4539777381
E-mail: [email protected]

Received date: January 14, 2013; Accepted date: January 24, 2013; Published date: February 01, 2013

Citation: Iversen AZ, Galatius S, Pedersen S, Abildgaard U, Jensen JS (2013) Mortality Reduction with Administration of Abciximab during Primary PCI is Confined to STEMI Patients with Complex Lesions. Cardiol Pharmacol 2:103. doi: 10.4172/2329-6607.1000103

Copyright: © 2013 Iversen AZ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided th original author and source are credited.

Abstract

Aim: The optimal timing of abciximab administration (´up-stream´/´in-cath-lab´) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI) is unclear. Data suggest that patients with high-risk profiles benefit from abciximab the most. Complex lesion on coronary angiography (CAG) implies a high-risk profile. Thus, we aimed to investigate whether lesion type (complex/simple) predicted the effect of abciximab in STEMI-patients undergoing pPCI.

Methods and results: 2,935 STEMI-patients treated with pPCI were retrospectively stratified according
to lesion type on CAG (complex/simple) and use of abciximab. Endpoints at 1 year were mortality, target vessel revascularization (TVR), myocardial infarction (MI), and the combination of these. Forty-seven percent had complex lesion on CAG. Among those, abciximab reduced one year mortality in both the univariate (from 12.7% to 7.8%, p=0.006) and the adjusted analysis (HR 0.62, CI 0.42-0.91, p=0.015). Patients with simple lesions had no mortality benefit of abciximab. Effect of abciximab on TVR or MI was neutral. Regarding the combined endpoint, abciximab treatment conferred a risk reduction in patients with complex lesions.

Conclusion: Benefit of abciximab in STEMI-patients undergoing pPCI was confined to those with complex lesions on CAG. Consequently, early abciximab treatment without knowledge of the lesion type may not be recommended

Keywords

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7